Analysis

Novocure Limited (NVCR) Stock Analysis

Novocure Limited investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to NVCR.

websiteNVCR/analysis/NVCR

Novocure Limited

Novocure Limited investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to NVCR.

Stock profile

Ticker

NVCR

Asset type

Stock

Market cap

$1.65B

Sector

Health Technology

Industry

Medical Specialties

Currency

USD

Ticker listings

Novocure Limited may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.

  • NVCR primary listing
  • 038
  • A140ML
  • N2VC34
  • NVCRN

Latest Novocure Limited news

Novocure Announces Topline Data from the Phase 3 TRIDENT Trial Evaluating Earlier Use of Tumor Treating Fields Therapy in Newly Diagnosed...

Novocure Announces Topline Data from the Phase 3 TRIDENT Trial Evaluating Earlier Use of Tumor Treating Fields Therapy in Newly Diagnosed

Novocure Reports First Quarter 2026 Financial Results

BAAR, Switzerland, April 30, 2026--Novocure (NASDAQ: NVCR) today reported financial results for the first quarter that ended March 31, 2026. Novocure is a global oncology compan...

Novocure to Report First Quarter 2026 Financial Results

BAAR, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) will report financial results for the first quarter 2026 on April 30, 2026, before the U.S.

Novocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastat...

BAAR, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) announced positive results today from the Phase 2 PANOVA-4 trial of Tumor Treating Fields

Novocure Announces Optune Lua® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer

Novocure to launch Optune Lua in Japan with national reimbursement coverage BAAR, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) announced today that

Research sections

Valuation

Review valuation context for Novocure Limited.

Future growth

Review future growth context for Novocure Limited.

Past performance

Review past performance context for Novocure Limited.

Financial health

Review financial health context for Novocure Limited.

Dividend

Review dividend context for Novocure Limited.

Management

Review management context for Novocure Limited.

Ownership

Review ownership context for Novocure Limited.

Other information

Review other information context for Novocure Limited.

Community

Review community context for Novocure Limited.